Mitochondrial Medicine

Planning for the Future: Monitoring and Systemic Health

At a Glance

Autosomal recessive progressive external ophthalmoplegia can extend beyond the eyes, so monitoring should be tailored to the gene and age of onset and may include heart, liver, nerve, swallowing, and breathing checks. Know emergency signs and discuss family planning with a genetic counselor.

While arPEO often begins as an eye condition, it is fundamentally a systemic genetic disorder. This means that while your eyes may be the only part of your body showing symptoms now, the “mitochondrial maintenance” defect exists in all your cells ^[1]. For many, the condition remains limited to the eyes, but for others, it can evolve into PEO-plus, involving other organ systems over many years ^[2]^[3].

Long-Term Surveillance

Because mitochondrial diseases can be “silent” before symptoms appear, the Mitochondrial Medicine Society recommends a proactive, multidisciplinary approach to monitoring ^[4]. Your care team should tailor a schedule based on your specific gene (such as POLG or RRM2B) and your age of onset ^[5]. (Note: Surveillance intervals should be individualized by your treating team based on your specific gene and phenotype, as these are examples of gene-specific surveillance rather than a fixed schedule for all patients).

Neurological: Regular checks for ataxia (balance issues) and peripheral neuropathy (numbness or tingling). In a study of POLG patients, these symptoms were more common in those diagnosed between ages 12 and 40 ^[6].
Cardiac: Baseline and periodic EKGs (electrocardiograms) are essential. Some mitochondrial defects can cause “heart block” or rhythm changes that you might not feel until they become serious ^[7]^[4].
Hepatic: Liver function tests are critical, especially for those with POLG mutations, as this gene is closely linked to liver health ^[8]^[6].
Bulbar and Respiratory: Periodic assessment of swallowing (dysphagia) and breathing strength is recommended, particularly if you notice morning headaches or daytime sleepiness ^[9]^[10].

Emergency “Red Flags”

In the context of arPEO, certain symptoms require immediate emergency evaluation. These are rare, but knowing them is vital for your safety.

Seek Emergency Care Immediately for:

Seizures or Status Epilepticus: Any new seizure, a seizure that lasts more than 5 minutes, or multiple seizures without waking up in between ^[11]^[12].
Acute Liver Failure: Signs include sudden yellowing of the skin or eyes (jaundice), intense vomiting with confusion (lethargy), or unexplained bleeding ^[8]^[13]. This is a high risk if a person with a POLG mutation is accidentally given Valproate ^[14].
Cardiac Events: Unexplained fainting (syncope), severe palpitations, or sudden, extreme shortness of breath ^[7]^[4].
Bulbar Crisis: Sudden inability to swallow or frequent choking/aspiration while eating ^[9].

Genetic Counseling and Family

Since arPEO is autosomal recessive, each of your biological parents typically carries one copy of the mutated gene ^[15].

Risk to Siblings: When parental genotype is established and variants are pathogenic, each of your full biological siblings has a 25% chance of also having the condition, even if they currently have no symptoms ^[16].
Risk to Children: Usually, your children will be “carriers” unless your partner carries a pathogenic variant in the same gene (which raises the risk to 50%).
Family Planning: For those considering having children, preimplantation genetic testing for a monogenic condition (PGT-M) or prenatal testing may be options to discuss with a genetic counselor ^[16]^[17].

Understanding Your Outlook

Your prognosis—the likely course of your condition—is often influenced by when your symptoms first appeared. Research shows that late-onset arPEO (starting in adulthood) typically progresses very slowly and is more likely to remain focused on the eyes and balance for many decades ^[6]^[18]. While these symptoms are life-altering, many people with isolated adult-onset arPEO have a relatively preserved lifespan, while some PEO-plus syndromes are more serious. Knowledge and consistent monitoring are your best tools for maintaining your health and independence ^[5].

Common questions in this guide

What parts of my body should be monitored with arPEO?

Although arPEO may begin with eye symptoms, it can affect the nervous system, heart, liver, swallowing muscles, and breathing. Your monitoring plan should be based on your gene, age when symptoms began, and current symptoms, with coordination among relevant specialists.

How often do I need heart and liver checks for arPEO?

Most people should have a baseline and periodic EKG, but the interval is individualized by the treating team. Liver function testing is especially important when a POLG mutation is present, even if you feel well.

When is an arPEO symptom an emergency?

Seek immediate emergency care for a new seizure, a seizure lasting more than five minutes, or repeated seizures without waking; jaundice, severe vomiting with confusion, or unexplained bleeding; fainting, severe palpitations, or sudden severe shortness of breath; or sudden inability to swallow or repeated choking. These can signal serious neurologic, liver, heart, or swallowing complications.

Why should some people with arPEO avoid valproate?

Valproate can trigger acute liver failure in people with certain POLG mutations. If you have a POLG-related condition, ask every clinician to review your genetic diagnosis before prescribing medicines and keep a clear emergency plan that identifies valproate as a medication to avoid.

What is the inheritance risk for my family with arPEO?

When both parents carry a pathogenic variant in the same gene, each full biological sibling has a 25% chance of having arPEO, even without symptoms. A person with arPEO will usually have children who are carriers; if the partner carries a pathogenic variant in the same gene, the chance of an affected child can be 50%.

What is the outlook for someone with adult-onset arPEO?

Late-onset arPEO often progresses slowly and may remain focused on the eyes and balance for decades. Many people with isolated adult-onset disease have a relatively preserved lifespan, but PEO-plus forms can be more serious, so regular monitoring remains important.

What family-planning options can I discuss for arPEO?

A genetic counselor can explain preimplantation genetic testing for a monogenic condition, also called PGT-M, and prenatal testing based on your exact gene and family situation. Counseling can also help relatives understand carrier testing and reproductive risks.

Get notified when new evidence is published on Autosomal recessive progressive external ophthalmoplegia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

arPEO may remain limited to the eyes, but some people develop PEO-plus involving the nervous system, heart, liver, swallowing, or breathing.
Surveillance should be tailored to the causative gene, age at onset, and symptoms and may include EKGs, liver function tests, neurologic checks, and swallowing and breathing assessments.
New seizures, signs of acute liver failure, fainting or severe palpitations, sudden breathlessness, or inability to swallow require immediate emergency evaluation; people with certain POLG mutations may need to avoid valproate.
Late-onset arPEO often progresses slowly and many people with isolated adult-onset disease have a relatively preserved lifespan, but PEO-plus forms can be more serious.
Because arPEO is autosomal recessive, genetic counseling can clarify sibling risks and options such as PGT-M or prenatal testing.

References (18)

1
Mitochondrial DNA maintenance defects.
El-Hattab AW, Craigen WJ, Scaglia F
Biochimica et biophysica acta. Molecular basis of disease 2017; (1863(6)):1539-1555 doi:10.1016/j.bbadis.2017.02.017.
PMID: 28215579
2
POLG-related disorders and their neurological manifestations.
Rahman S, Copeland WC
Nature reviews. Neurology 2019; (15(1)):40-52 doi:10.1038/s41582-018-0101-0.
PMID: 30451971
3
Clinical, Histological, and Genetic Features of 25 Patients with Autosomal Dominant Progressive External Ophthalmoplegia (ad-PEO)/PEO-Plus Due to TWNK Mutations.
Bermejo-Guerrero L, de Fuenmayor-Fernández de la Hoz CP, Serrano-Lorenzo P, et al.
Journal of clinical medicine 2021; (11(1)) doi:10.3390/jcm11010022.
PMID: 35011763
4
Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.
Parikh S, Goldstein A, Karaa A, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(12)) doi:10.1038/gim.2017.107.
PMID: 28749475
5
[An interpretation of the expert consensus on standards for the management of patients with primary mitochondrial disease from the Mitochondrial Medicine Society].
Guo Y, Hong SQ, Jiang L
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2018; (20(11)):887-892.
PMID: 30477617
6
Simplifying the clinical classification of polymerase gamma (POLG) disease based on age of onset; studies using a cohort of 155 cases.
Hikmat O, Naess K, Engvall M, et al.
Journal of inherited metabolic disease 2020; (43(4)):726-736 doi:10.1002/jimd.12211.
PMID: 32391929
7
Sudden adult death syndrome in m.3243A>G-related mitochondrial disease: an unrecognized clinical entity in young, asymptomatic adults.
Ng YS, Grady JP, Lax NZ, et al.
European heart journal 2016; (37(32)):2552-9 doi:10.1093/eurheartj/ehv306.
PMID: 26188002
8
Juvenile/adult-onset POLG-related disease unmasked by valproate-associated fulminant hepatic failure.
Mathavan A, Rathi K, Mundhra LJ, Mathavan A
BMJ case reports 2025; (18(12)) doi:10.1136/bcr-2025-269373.
PMID: 41381198
9
Speech and swallowing abnormalities in adults with POLG associated ataxia (POLG-A).
Vogel AP, Rommel N, Oettinger A, et al.
Mitochondrion 2017; (37()):1-7 doi:10.1016/j.mito.2017.06.002.
PMID: 28634151
10
Exploring Outcome Measures for Mitochondrial Myopathies; Insights From a Longitudinal Study on TK2 Deficiency.
Martín-Jimenez P, Bermejo-Guerrero L, Ochoa LE, et al.
Journal of inherited metabolic disease 2026; (49(1)):e70147 doi:10.1002/jimd.70147.
PMID: 41571587
11
Understanding the Epilepsy in POLG Related Disease.
Hikmat O, Eichele T, Tzoulis C, Bindoff LA
International journal of molecular sciences 2017; (18(9)) doi:10.3390/ijms18091845.
PMID: 28837072
12
Epilepsy due to mutations in the mitochondrial polymerase gamma (POLG) gene: A clinical and molecular genetic review.
Anagnostou ME, Ng YS, Taylor RW, McFarland R
Epilepsia 2016; (57(10)):1531-1545 doi:10.1111/epi.13508.
PMID: 27554452
13
Acute Liver Failure following Valproate Exposure in a Teenager with Homozygous POLG c.2243G>C (p.Trp748Ser) Mutation: Late-Onset Presentation and Successful Liver Transplantation - A Case Report.
Bingol I, Umur O, Sık SG, et al.
Molecular syndromology 2026; doi:10.1159/000552241.
PMID: 42369769
14
The mitochondrial epilepsies.
Lim A, Thomas RH
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2020; (24()):47-52 doi:10.1016/j.ejpn.2019.12.021.
PMID: 31973983
15
Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO.
Hedberg-Oldfors C, Macao B, Basu S, et al.
Neurology. Genetics 2020; (6(1)):e391 doi:10.1212/NXG.0000000000000391.
PMID: 32042919
16
Targeted next-generation sequencing analysis in couples at increased risk for autosomal recessive disorders.
Komlosi K, Diederich S, Fend-Guella DL, et al.
Orphanet journal of rare diseases 2018; (13(1)):23 doi:10.1186/s13023-018-0763-0.
PMID: 29373990
17
Application of next generation sequencing in genetic counseling a case of a couple at risk of cystinosis.
Ouhenach M, Zrhidri A, Jaouad IC, et al.
BMC medical genetics 2020; (21(1)):240 doi:10.1186/s12881-020-01167-y.
PMID: 33308164
18
Retrospective natural history of thymidine kinase 2 deficiency.
Garone C, Taylor RW, Nascimento A, et al.
Journal of medical genetics 2018; (55(8)):515-521 doi:10.1136/jmedgenet-2017-105012.
PMID: 29602790

This page explains long-term monitoring and family planning for arPEO for educational purposes only and does not replace medical advice. Ask your mitochondrial disease team or genetic counselor to tailor surveillance, medication precautions, and testing to your situation.